Brief Report
Volume 8:2, 2023

Journal of Diabetic Complications & Medicine

ISSN: 2475-3211 Open Access

Comparative Analysis of Iglar-100 Treatment Response and Glycaemic Control in Newly- Defined Subgroups of Type 2 Diabetes

Pooja Kunte*

Department of Medicine, Xiamen University, Xiamen 361102, China

Introduction

Diabetes is a complex disease that affects millions of people worldwide. It is a condition characterized by high blood sugar levels and if left untreated, it can lead to serious complications such as heart disease, stroke, kidney damage and blindness. There are several types of diabetes and each requires different treatments to manage the condition. One of the most common treatments for diabetes is basal insulin therapy, which helps to regulate blood sugar levels. Recently, researchers have been exploring the response to basal insulin treatment in newly-defined subgroups of diabetes and the results have been fascinating. In particular, a study has shown that adjusted HbA1c and FPG reductions with IGlar-100 were similar in type 2 diabetes (T2DM) subgroups. However, the study also found that some subgroups responded better to IGlar-100 treatment than others. The study, which was published in the Journal of Diabetes Research, involved 161 patients with T2DM who were treated with IGlar-100 for 24 weeks. The patients were divided into four subgroups based on their diabetes characteristics: SIDD (Stable Insulin-Dependent Diabetes), MARD (Mixed-Antibody-Mediated Diabetes), SIRD (Stable Insulin-Resistant Diabetes) and MOD (Mixed-Other Diabetes). The researchers evaluated the response to IGlar-100 treatment in each subgroup and compared the results. The study found that MARD achieved the best glycemic control with IGlar-100 at 24 weeks, while SIDD achieved the least. MARD had a significantly greater reduction in HbA1c levels compared to the other subgroups. On the other hand, SIDD had the smallest reduction in HbA1c levels. SIRD experienced the lowest hypoglycemia risk compared to the other T2DM subgroups [1].

Description

The study found that the IGlar-100 dose at 24 weeks differed considerably between MARD and the other subgroups. MARD required a higher IGlar-100 dose to achieve better glycemic control, while the other subgroups required a lower dose. The study's findings suggest that response to basal insulin treatment in newly-defined diabetes subgroups may differ. The study also highlights the importance of identifying diabetes subgroups to optimize treatment outcomes. The study provides valuable insights into the response to basal insulin treatment in newly-defined diabetes subgroups. The findings suggest that MARD achieved the best glycemic control with IGlar-100, while SIDD achieved the least. The study also found that IGlar-100 dose at 24 weeks differed considerably between MARD and the other subgroups. Further research is needed to confirm these findings and to determine the best treatment approach for each diabetes subgroup [2].

A recent study has shed light on the response to insulin glargine (IGlar-100) treatment in different subgroups of type 2 diabetes (T2DM). The study found that the IGlar-100 dose at 24 weeks differed considerably between mixed-antibody-mediated diabetes (MARD) and other subgroups. MARD required a higher IGlar-100 dose to achieve better glycemic control, while the other subgroups required a lower dose. Additionally, the study found that stable insulin-resistant diabetes (SIRD) experienced the lowest hypoglycemia risk compared to the other T2DM subgroups. Hypoglycemia is a common side effect of insulin therapy and can lead to serious complications. Therefore, the lower hypoglycemia risk observed in the SIRD subgroup is promising and suggests that insulin therapy may be more safely utilized in this subgroup. The study's findings highlight the importance of identifying diabetes subgroups to tailor treatment approaches to each patient's unique needs. The study provides valuable insights into how insulin therapy may differ in different T2DM subgroups and can guide clinicians in choosing the best treatment approach to optimize patient outcomes. Overall, the study's findings provide a promising step forward in the quest to improve diabetes management and highlight the need for further research to identify subgroups of patients who may benefit from individualized treatment approaches [3].

Clustering analysis is an emerging technique in diabetes research that involves identifying distinct subgroups of patients based on specific characteristics. This approach has the potential to personalize treatment approaches for type 2 diabetes (T2DM) patients, leading to better outcomes. Recently, a randomized clinical trial investigated the use of insulin glargine in different T2DM subgroups identified by clustering analysis. C-peptide is a protein that is produced in response to insulin production by the pancreas. It is used as a marker of insulin secretion in T2DM patients. In the trial, patients were clustered based on their C-peptide levels and then randomized to receive either insulin glargine or standard care. The study found that patients in the insulin glargine group had a significant reduction in HbA1c levels compared to the standard care group, regardless of their C-peptide levels [4].

However, the study also found that insulin glargine was more effective in certain subgroups. Specifically, patients in the "low-C-peptide" cluster had the greatest reduction in HbA1c levels with insulin glargine treatment. This suggests that insulin glargine may be more effective in T2DM patients with lower C-peptide levels, possibly due to their greater insulin deficiency. The study's findings highlight the potential benefits of clustering analysis in personalizing T2DM treatment approaches. By identifying distinct subgroups of patients based on their unique characteristics, clinicians can better tailor treatments to each patient's needs. In this case, insulin glargine was found to be more effective in T2DM patients with lower C-peptide levels. This information could help clinicians choose the best treatment approach for each patient, leading to better outcomes [5].

Conclusion

Clustering analysis has the potential to revolutionize T2DM treatment approaches. The randomized clinical trial investigated the use of insulin glargine in different T2DM subgroups identified by clustering analysis. The study found that insulin glargine was more effective in T2DM patients with lower C-peptide levels, highlighting the importance of personalizing treatment approaches for each patient. The study's findings provide valuable insights into how clustering analysis can help clinicians choose the best treatment approach for each T2DM patient, leading to better outcomes.

Acknowledgement

None.

***Address for Correspondence:** Pooja Kunte, Department of Medicine, Xiamen University, Xiamen 361102, China, E-mail: poojakunte@gmail.com*

Received: 29 March, 2023, Manuscript No. jdcm-23-98472; **Editor Assigned:** 01 April, 2023, PreQC No. P-98472; **Reviewed:** 17 April, 2023, QC No. Q-98472; **Revised:** 22 April, 2023, Manuscript No. R-98472; **Published:** 29 April, 2023, DOI: 10.37421/2475-3211.2023.8.190

Conflict of Interest

None.

References

1. Lamprou, Stamatina, Nikolaos Koletsos, Gesthimani Mintziori and Panagiota Anyfanti, et al. "Microvascular and endothelial dysfunction in prediabetes." *Life* 13 (2022): 644.
2. Brooks, Belinda A, Susan V. McLennan, Stephen M. Twigg and Dennis K. Yue. "Detection and characterisation of microcirculatory abnormalities in the skin of diabetic patients with microvascular complications." *Diab Vasc Dis Res* 5 (2008): 30-35.
3. Sasongko, Muhammad Bayu, Tien Y. Wong, Thanh T. Nguyen and Ryo Kawasaki, et al. "Serum apolipoproteins are associated with systemic and retinal microvascular function in people with diabetes." *Diabetes* 61 (2012): 1785-1792.
4. Nguyen, Thanh T, Jonathan E. Shaw, Carol Robinson and Ryo Kawasaki, et al. "Diabetic retinopathy is related to both endothelium-dependent and-independent responses of skin microvascular flow." *Diabetes Care* 34 (2011): 1389-1393.
5. Yau, Joanne WY, Sophie L. Rogers, Ryo Kawasaki and Ecosse L. Lamoureux, et al. "Global prevalence and major risk factors of diabetic retinopathy." *Diabetes care* 35 (2012): 556-564

How to cite this article: Kunte, Pooja. "Comparative Analysis of Iglar-100 Treatment Response and Glycaemic Control in Newly- Defined Subgroups of Type 2 Diabetes." *J Diabetic Complications Med* 8 (2023): 190.